FemAid, a medical device company focused on women's health, has completed the prototyping phase and filed a patent application for its non-surgical, non-drug incontinence device. The device utilizes a check valve placed in the urethra that can be adjusted to meet individual needs. It stops urine flow until activated by pressure on the bladder and is made with body-friendly Teflon material for ma..
Auxilius Pharma has raised $1 million in seed funding to develop its lead asset, AUX-001, a new medication for treating chronic-stable angina pectoris in the US. The company is developing the drug as there have been very few medications developed to address chest pain symptoms suffered by patients with underlying coronary artery disease. Auxilius plans to conduct a first-in-human exploratory pha..
Ascelia Pharma presented its Hepatic Impairment Study data, which was showcased at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting in Valencia, Spain, on June 13-16, 2023. The company also held a Q&A session to discuss liver imaging and unmet needs for patients suffering from severe kidney impairment. The Hepatic Impairment Study showed that Ascelia Pharma..
Telix Pharmaceuticals has announced the dosing of the first patient in a Phase II study of TLX250-CDx, an imaging agent that targets carbonic anhydrase (CAIX) and is being investigated across a range of cancer indications. The STARBURST study will explore CAIX expression in patients with diverse solid tumours for potential diagnostic and therapeutic applications. Tumours expressing CAIX are typi..
In order to keep top-performing employees, offering competitive pay and opportunities for advancement are not enough. According to Scott Rivers, president and managing partner of Cerca Talent, a robust employee retention strategy includes proactive recruitment of great people, fostering product development and innovation among employees, and safeguarding team culture. Rivers emphasizes that once..
The Bespoke Gene Therapy Consortium, managed by the Foundation for the National Institutes of Health (NIH), has selected eight rare diseases for its clinical trials program. The consortium aims to accelerate gene therapy development targeting rare diseases with few therapeutic options. The BGTC will develop protocols for first-in-human trials for Charcot-Marie-Tooth disease type 4J, congenital h..
The FDA is set to make four important decisions this week, including the approval of Argenx’s subcutaneous efgartigimod for adults with generalized myasthenia gravis, Aldeyra’s investigational intravitreal injection ADX-2191 for primary vitreoretinal lymphoma, Intercept Pharmaceuticals’ obeticholic acid for pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis, and Sarepta’s gene the..
Jubilant Therapeutics is preparing for Phase II and first-in-human trials later in 2023, with two Orphan Drug Designations, an advantageous safety profile and enhanced therapeutic indices. The company's pipeline is generated 100% in-house using its Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine, which permits the identification of candidate molecules with enhanced the..
Merck has finalized its acquisition of Prometheus Biosciences for $10.8 billion, gaining five candidates for inflammatory bowel and immune-mediated diseases, including the leading candidate MK-7240 for ulcerative colitis and Crohn's disease. The purchase marks Merck's further expansion into the immunology space. The all-cash agreement includes buying all outstanding shares of Prometheus at a 75%..
Eli Lilly's Emgality drug failed to demonstrate statistical superiority over Pfizer's Nurtec in the CHALLENGE-MIG trial. The proportion of patients experiencing a 50% reduction in migraine headache days per month was statistically similar between the two drugs, although Emgality did achieve clinically meaningful efficacy and safety outcomes compared to a placebo. The CHALLENGE-MIG study is the f..
